New biosimilar aims to match opdivo for melanoma
NCT ID NCT07476326
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests whether a new drug called Bmab1700 works the same as the approved immunotherapy Opdivo in people with melanoma who have had their tumors surgically removed. The trial will involve 120 adults with stage IIB to IV melanoma. Researchers will compare how the drugs move through the body, their safety, and how the immune system reacts to them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Biocon Investigational Site
Bento Gonçalves, Brazil
-
Biocon Investigational Site
Ijuí, Brazil
-
Biocon Investigational Site
Pará, Brazil
-
Biocon Investigational Site
Porto Alegre, Brazil
-
Biocon Investigational Site
Rio de Janeiro, Brazil
-
Biocon Investigational Site
Santa Catarina, Brazil
-
Biocon Investigational Site
São Paulo, Brazil
-
Biocon Investigational Site
Providencia, Chile
-
Biocon Investigational Site
Recoleta, Chile
-
Biocon Investigational Site
Santiago, Chile
-
Biocon Investigational Site
Batumi, Georgia
-
Biocon Investigational Site
Kutaisi, Georgia
-
Biocon Investigational Site
Tbilisi, Georgia
-
Biocon Investigational Site
Chisinau, Moldova
-
Biocon Investigational Site
Bucharest, Romania
-
Biocon Investigational Site
Craiova, Romania
-
Biocon Investigational Site
Belgrade, Serbia
-
Biocon Investigational Site
Kamenitz, Serbia
-
Biocon Investigational Site
Kragujevac, Serbia
-
Biocon Investigational Site
Niš, Serbia
-
Biocon Investigational Site
George, South Africa
-
Biocon Investigational Site
Johannesburg, South Africa
-
Biocon Investigational Site
Port Elizabeth, South Africa
-
Biocon Investigational Site
Barcelona, Spain
-
Biocon Investigational Site
Madrid, Spain
-
Biocon Investigational Site
Murcia, Spain
-
Biocon Investigational Site
Sabadell, Spain
-
Biocon Investigational Site
Seville, Spain
-
Biocon Investigational Site
Ankara, Turkey (Türkiye)
-
Biocon Investigational Site
Bornova, Turkey (Türkiye)
-
Biocon Investigational Site
Konak, Turkey (Türkiye)
-
Biocon Investigational Site
Ivano-Frankivsk, Ukraine
-
Biocon Investigational Site
Kyiv, Ukraine
-
Biocon Investigational Site 1
Santa Catarina, Brazil
-
Biocon Investigational Site 1
São Paulo, Brazil
-
Biocon Investigational Site 1
Santiago, Chile
-
Biocon Investigational Site 1
Tbilisi, Georgia
-
Biocon Investigational Site 1
Belgrade, Serbia
-
Biocon Investigational Site 1
Johannesburg, South Africa
-
Biocon Investigational Site 1
Barcelona, Spain
-
Biocon Investigational Site 1
Seville, Spain
-
Biocon Investigational Site 2
Santa Catarina, Brazil
-
Biocon Investigational Site 2
São Paulo, Brazil
-
Biocon Investigational Site 2
Tbilisi, Georgia
-
Biocon Investigational Site 3
Tbilisi, Georgia
-
Biocon Investigational Site 4
Tbilisi, Georgia
-
Biocon Investigational Site 5
Tbilisi, Georgia
-
Site 26
Cluj-Napoca, Romania
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?